Kemp Dolliver

Stock Analyst at Brookline Capital

(0.68)
# 4,076
Out of 5,172 analysts
19
Total ratings
38.46%
Success rate
-12.22%
Average return

Stocks Rated by Kemp Dolliver

Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $5.01
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.24
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $5.45
Upside: +211.93%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.80
Upside: +275.39%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.09
Upside: +72.25%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.36
Upside: +2,547.06%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.35
Upside: +8,843.32%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $76.43
Upside: +30.84%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $7.35
Upside: +675.51%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.40
Upside: +941.67%
Initiates: Buy
Price Target: $19
Current: $6.25
Upside: +200.00%
Assumes: Buy
Price Target: $8
Current: $0.93
Upside: +758.09%
Initiates: Buy
Price Target: $5.65
Current: $0.63
Upside: +799.11%